RxDoctor Payments Data

Fei Yu, MD

Internal Medicine · Englewood Cliffs, NJNPI 1790727444

Payments from drug & device makers

$1,342in general payments, 2019–2025

Across 38 payments — averaging $35.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$634
  • Novartis$177
  • Bayer$125
  • Amgen$66
  • Amarin Pharma, Inc.$58
  • Pfizer$56
  • plus $226 from 8 others

What the payments were for

  • Food & beverage$1,342100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,342 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$109,184
Medicare patients
223
Services billed
1,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl127$61,579
EliquisApixaban46$48,561
JardianceEmpagliflozin21$30,940
VemlidyTenofovir Alafenamide13$21,782
JanuviaSitagliptin Phosphate22$20,018
XareltoRivaroxaban26$19,250
FarxigaDapagliflozin Propanediol14$13,996
TrulicityDulaglutide11$9,915
RestasisCyclosporine12$7,795
Atorvastatin Calcium651$5,665
Icosapent Ethyl22$4,967
Losartan Potassium433$3,480
Metoprolol Succinate161$3,004
Diclofenac Sodium28$2,541
Zolpidem Tartrate137$2,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$48,56146 claims
Boehringer IngelheimJardiance$634$30,94021 claims
AstraZenecaFarxiga$15$13,99614 claims
Lilly USA, LLCTrulicity$42$9,91511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Englewood Cliffs

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →